Synbio International Secures Exclusive Nutraceutical Licensing Deal, Paving the Way for Near-Term Revenue

Synbio International, Inc. (OTC: SYIN) has taken a significant step toward generating revenue by entering into an exclusive licensing, manufacturing, supply, and revenue-sharing agreement with MD PHD Wellness, Inc. The deal grants Synbio exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations across the United States and Canada. The collaboration covers MD PHD Wellness' flagship anti-anxiety nutraceutical, which will be marketed under Synbio's Healing Force™ brand, and establishes a framework for evaluating additional wellness products in the future.

This strategic move provides Synbio with immediate access to proprietary products without the substantial time and cost typically required for in-house development. Under the agreement, MD PHD Wellness will manage product development, manufacturing, quality assurance, and supply chain, while Synbio will focus on branding, marketing, sales, and distribution. Profits from product sales will be shared between the parties after recovering approved commercialization costs, aligning incentives for both companies.

Claudio Solitario, CEO of Synbio International, described the agreement as a "transformational milestone" for the company. He emphasized that instead of building a nutraceutical business product by product, Synbio now has a strategic partnership that combines MD PHD's development and manufacturing expertise with Synbio's commercialization capabilities. "It gives Synbio immediate access to proprietary products capable of generating near-term commercial revenue while establishing a framework to expand our wellness portfolio over time," Solitario said. He added that the partnership allows management to focus on building brands, generating sales, and expanding market presence, which he believes is the most direct path to creating shareholder value.

The global nutraceutical market is experiencing rapid growth, driven by increasing consumer interest in health and wellness. By leveraging MD PHD Wellness's scientifically developed products, Synbio is positioning itself to participate in this expanding market. At the same time, the company continues to advance its longer-term AI-driven healthcare technologies, which are focused on screening for mental health conditions using facial analysis. This dual-track approach pairs near-term revenue from wellness products with the potential for high-impact innovations in mental health diagnostics, providing multiple avenues for growth and financial stability.

The scientific leadership behind the licensed formulations adds credibility to the venture. MD PHD Wellness was founded by Dr. Robert Lawrence, a physician and scientist with two Ph.D.s in Nuclear Physics and Biomedical Engineering. His career encompasses medicine, biomedical engineering, microbiology, pharmacology, and nutraceutical development, with research in cellular regeneration and natural product delivery systems. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the proprietary formulations and has extensive expertise in nutraceuticals and scientific claims substantiation. His background includes serving as a Research Physician at a prominent New York-based university, where he participated in evaluating therapeutics and emerging healthcare technologies.

Synbio's strategy reflects a pragmatic approach to building a diversified healthcare company. By securing a pipeline of proprietary products through partnerships, the company can generate recurring revenue to support its ongoing investment in AI-driven mental health tools. This approach may appeal to investors seeking near-term commercial traction without waiting for lengthy research and development cycles. However, the success of this venture will depend on effective marketing, regulatory compliance, and consumer acceptance of the nutraceutical products.

As Synbio moves forward, the company plans to launch its nutraceutical products directly to consumers online in 2026. The licensing agreement with MD PHD Wellness not only accelerates Synbio's path to revenue but also establishes a foundation for long-term portfolio expansion. With a clear division of responsibilities and shared profit incentives, both companies are poised to benefit from the growing demand for wellness products. This partnership represents a calculated step toward establishing Synbio as a player in the health and wellness industry while it continues to pursue its broader vision of integrating AI into mental health care.